SEC Filing Summary for Akari Therapeutics Plc

On August 18, 2026, Robert B. Bazemore, a director at Akari Therapeutics Plc (AKTX), was granted stock options to purchase 45,000 ADSs at an exercise price of $7.899 per ADS and 15,000 ADSs at an exercise price of $7.899 per ADS. These options are subject to forfeiture and specific vesting schedules tied to shareholder approval of an equity incentive plan amendment. Additionally, on the same date, Bazemore acquired 13,100 ADSs, also subject to forfeiture pending shareholder approval. On October 5, 2026, he acquired another 4,677 ADSs, similarly contingent on shareholder approval. On October 14, 2026, Bazemore